Acute myocardial infarction Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Th

The Acute Myocardial Infarction market size in the 7MM is estimated to be around USD 1,600 million in 2023 and is expected to increase with a significant CAGR during the forecast period.

Emerging therapies for acute myocardial infarction (AMI), including LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and others, are anticipated to drive growth in the AMI market over the coming years.

DelveInsight has introduced a new report titled "Acute Myocardial Infarction - Market Insights, Epidemiology, and Market Forecast-2034", offering a comprehensive analysis of the condition, its historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Acute myocardial infarction market report @ https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Acute myocardial infarction Market Report:

*
The acute myocardial infarction (AMI) market across the 7MM was valued at approximately USD 1.6 billion in 2023 and is projected to grow at a strong CAGR through the forecast period. The United States dominated the market, accounting for nearly 75% of the total share.

*
In 2023, there were an estimated 1.47 million incident cases of AMI in the 7MM, with the US reporting the highest burden at around 822,800 new cases, a figure expected to rise by 2034. Within subtypes, NSTEMI cases outnumbered STEMI, with about 607,300 NSTEMI cases reported in the US alone. In Japan, incident cases included roughly 45,700 STEMI and 34,500 NSTEMI, while in the EU4 and the UK, there were around 930,900 male and 537,500 female cases of AMI in 2023.

*
Recent regulatory milestones are shaping the treatment landscape. The FDA approved AGEPHA Pharma's LODOCO for patients with residual inflammatory risk, marking the first therapy to directly target inflammatory pathways driving cardiovascular events. Additionally, novel platelet antagonists such as Zalunfiban and Selatogrel are showing promise with subcutaneous administration at first medical contact for STEMI patients. In April 2024, the FDA also granted Breakthrough Device Designation to PMcardio's STEMI AI ECG Model, an AI-based platform designed to analyze 12-lead ECGs for rapid detection of STEMI and other cardiac conditions.

*
The AMI market outlook is expected to evolve further, supported by advances in diagnostics, increased awareness, and rising healthcare expenditure. Key industry players-including Idorsia Pharmaceuticals, Viatris, Recardio, Amgen, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CeleCor Therapeutics, Kancera, CellProthera, BioCardia, AstraZeneca, Arrowhead Pharmaceuticals, and others-are actively progressing clinical candidates.

*
Notable pipeline therapies include LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and additional investigational agents poised to transform the treatment landscape between 2024 and 2034.

Acute myocardial infarction Overview

Acute Myocardial Infarction (AMI), commonly referred to as a heart attack, is a serious condition that occurs when blood flow to a section of the heart muscle is suddenly obstructed. This usually happens due to a blockage in one of the coronary arteries, which are responsible for delivering oxygen and nutrients to the heart.

AMI is a frequent outcome of cardiovascular disease (CVD), particularly in older adults, and is associated with a high risk of mortality, complications, and significant healthcare costs. While several effective post-infarction treatments exist, current guidelines recommend lifelong preventive therapy-typically including beta-blockers, ACE inhibitors or angiotensin II receptor blockers, acetylsalicylic acid, and statins-unless contraindications are present.

Acute myocardial infarction Market Outlook

A number of leading pharmaceutical companies are actively developing therapies for acute myocardial infarction (AMI), including Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Arrowhead Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera, BioCardia, Mesoblast, and others. Detailed insights into market size by therapy and country are outlined below.

Within the 7MM, the United States accounted for the largest share of the AMI market in 2023, while Spain represented the smallest, with a market size of about USD 25 million.

Among pipeline therapies anticipated to enter the market during the forecast period, Ziltivekimab is expected to generate the highest revenue by 2034.

Discover how the Acute myocardial infarction market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Acute myocardial infarction marketed drugs

*
LODOCO (colchicine): AGEPHA Pharma

*
TNKase (tenecteplase): Genentech

Acute myocardial infarction Emerging Drugs

*
Dutogliptin: Recardio

*
Selatogrel: Idorsia Pharmaceuticals and Viatris

Scope of the Acute myocardial infarction Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Acute myocardial infarction Companies: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, and others

*
Key Acute myocardial infarction Therapies: LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and others

*
Acute myocardial infarction Therapeutic Assessment: Acute myocardial infarction current marketed and Acute myocardial infarction emerging therapies

*
Acute myocardial infarction Market Dynamics: Acute myocardial infarction market drivers and Acute myocardial infarction market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Acute myocardial infarction Unmet Needs, KOL's views, Analyst's views, Acute myocardial infarction Market Access and Reimbursement

To know what's more in our Acute myocardial infarction report, visit https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Acute myocardial infarction Market Report:

*
Acute myocardial infarction market report covers a descriptive overview and comprehensive insight of the Acute myocardial infarction Epidemiology and Acute myocardial infarction market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Acute myocardial infarction market report provides insights into the current and emerging therapies.

*
The Acute myocardial infarction market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Acute myocardial infarction market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute myocardial infarction market.

Got queries? Click here to know more about the Acute myocardial infarction market Landscape [https://www.delveinsight.com/sample-request/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Acute myocardial infarction Patient Share (%) Overview at a Glance

5. Acute myocardial infarction Market Overview at a Glance

6. Acute myocardial infarction Disease Background and Overview

7. Acute myocardial infarction Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute myocardial infarction

9. Acute myocardial infarction Current Treatment and Medical Practices

10. Unmet Needs

11. Acute myocardial infarction Emerging Therapies

12. Acute myocardial infarction Market Outlook

13. Country-Wise Acute myocardial infarction Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Acute myocardial infarction Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Acute myocardial infarction Market Outlook 2034 [https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Acute myocardial infarction Pipeline Insights, DelveInsight

"Acute myocardial infarction Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute myocardial infarction market. A detailed picture of the Acute myocardial infarction pipeline landscape is provided, which includes the disease overview and Acute myocardial infarction treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-myocardial-infarction-market-analysis-epidemiology-insights-therapies-companies-by-delveinsight-idorsia-pharmaceuticals-viatris-recardio-astrazeneca-faraday-pharmaceuticals-celecor-th]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.